Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1662 | Fiberoptic Endoscopic Evaluation of Swallowing Wiki | 0.58 |
| drug4953 | feces samples (COVI-BIOME ancillary study) Wiki | 0.41 |
| drug4860 | blood sample for seroepidemiological investigation Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug5252 | sweat samples (COVIDOG ancillary study) Wiki | 0.41 |
| drug2982 | Optimal-Massive Intervention Wiki | 0.41 |
| drug1118 | Control (standard clinical practice) Wiki | 0.41 |
| drug1663 | Fibreoptic Endoscopic Evaluation of Swallowing (FEES) Wiki | 0.41 |
| drug1398 | Dysphagia Handicap Index (DHI) Wiki | 0.41 |
| drug4223 | Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) Wiki | 0.41 |
| drug4093 | Standard care delivered in the isolation hospitals. Wiki | 0.41 |
| drug4465 | Tramadol Wiki | 0.41 |
| drug4662 | Videofluoroscopy Wiki | 0.41 |
| drug4704 | Voice Symptom Scale (VoiSS) Wiki | 0.41 |
| drug4861 | blood samples Wiki | 0.29 |
| drug4859 | blood sample Wiki | 0.26 |
| drug4212 | Survey Wiki | 0.10 |
| drug1150 | Convalescent plasma Wiki | 0.09 |
| drug3195 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003680 | Deglutition Disorders NIH | 1.00 |
| D006685 | Hoarseness NIH | 0.41 |
| D003681 | Dehydration NIH | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D055154 | Dysphonia NIH | 0.41 |
| D014832 | Voice Disorders NIH | 0.41 |
| D013896 | Thoracic Diseases NIH | 0.29 |
| D009059 | Mouth Diseases NIH | 0.24 |
| D044342 | Malnutrition NIH | 0.20 |
| D002318 | Cardiovascular Diseases NIH | 0.07 |
| D004194 | Disease NIH | 0.06 |
| D012141 | Respiratory Tract Infections NIH | 0.06 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001609 | Hoarse voice HPO | 0.41 |
| HP:0001618 | Dysphonia HPO | 0.41 |
| HP:0001621 | Weak voice HPO | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001944 | Dehydration HPO | 0.41 |
| HP:0004395 | Malnutrition HPO | 0.20 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.07 |
| HP:0011947 | Respiratory tract infection HPO | 0.06 |
Navigate: Correlations HPO
There are 6 clinical trials
Background: Oropharyngeal dysphagia (OD) is a common complication in/post ICU patients that have been with intubation/mechanical ventilation or with tracheotomies or NG tubes, in patients with acute respiratory infection/pneumonia/respiratory insufficiency with a severe disease needing high concentration of oxygen or noninvasive mechanical ventilation and also in patients discharged from acute hospitals to rehabilitation centers, nursing homes or other facilities. All these situations are common for COVID-19 patients that are currently filling our hospitals due to the pandemic expansion of SARS-CoV-2. OD is associated to prolonged hospitalization, dehydration and severe nutritional and respiratory complications -aspiration pneumonia-, hospital readmissions and mortality. Aim: to assess the prevalence of OD and nutritional risk in these patients and to know their needs of compensatory treatment following the application of an early intervention, and to assess whether OD and malnutrition are indicators of poor prognosis for COVID-19 patients. Methods: prospective study in which we will use the volume-viscosity swallowing test (V-VST) to assess the prevalence of OD, and NRS2002 to assess the nutritional risk in admitted patients with confirmed COVID-19 at the Consorci Sanitari del Maresme, Catalonia, Spain. We will register also results of the EAT-10, nutritional status, the needs of compensatory treatments of these patients following an early intervention with fluid and nutritional adaptation and use of nutritional supplements. We will also collect other clinical variables from medical history of the patient related to hospitalization and we will follow the clinical complications and nutritional status at 3 and 6 months follow up.
Description: Changes in the prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).
Measure: Changes in the prevalence of oropharyngeal dysphagia Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points
Measure: Changes in the swallowing screening Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the percentage of patients with impairements in efficacy and/or safety of swallow.
Measure: Changes in the swallowing status Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).
Measure: Changes in the nutritonal status of study patient's. Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the fluid (volume and viscosity) requirements of study patients.
Measure: Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation). Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the nutritional adaptation requirements (type of diet and need of nutritional supplementation).
Measure: Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation). Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the incidence of hospital readmissions: number of hospital readmissions/patient/6 months.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (incidence of readmissions). Time: 3 and 6 months from inclusion.Description: Changes in the prevalence: % of patients with hospital readmissions during the follow-up.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (prevalence of readmissions). Time: 3 and 6 months from inclusion.Description: Incidence: number of visits to the emergency department/patient/ 3 or 6 months.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (number of visits to emergency department). Time: 3 and 6 months from inclusion.Description: Prevalence: % of patients visiting the emergency department during the follow-up.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (percentage of visits to emergency department). Time: 3 and 6 months from inclusion.Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (respiratory complications). Time: 3 and 6 months from inclusion.Description: 3 and 6 months mortality.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (mortality). Time: 3 and 6 months from inclusion.The proposed study seeks to determine the incidence of dysphagia and vocal fold mobility impairment (VFMI) in individuals undergoing throacic surgical procedures. It also seeks to determine the impact of postoperative swallowing impairment on health-related outcomes.
Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
Measure: Penetration Aspiration Scale Time: BaselineDescription: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).
Measure: Yale Residue Severity Rating Scale Time: BaselineDescription: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.
Measure: Vocal Fold Mobility Impairment Time: BaselineThe proposed study seeks to determine the incidence of dysphagia and vocal fold mobility impairment (VFMI) in individuals undergoing cardiovascular surgical procedures. It also seeks to determine the impact of postoperative swallowing impairment on health-related outcomes.
Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
Measure: Penetration Aspiration Scale Time: Baseline (Prior to surgery)Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
Measure: Penetration Aspiration Scale Time: Follow-up - Within 72 hours following extubation from surgeryDescription: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).
Measure: Yale Residue Severity Rating Scale Time: Baseline (Prior to surgery)Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).
Measure: Yale Residue Severity Rating Scale Time: Follow-up - Within 72 hours following extubation from surgeryDescription: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.
Measure: Vocal Fold Mobility Impairment Time: Baseline (Prior to surgery)Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.
Measure: Vocal Fold Mobility Impairment Time: Follow-up - Within 72 hours following extubation from surgeryThe current study is aimed to determine the procedures applied in the dysphagia clinics during the COVID-19 pandemic period. A questionnaire consisting of 30 questions will be implemented. Each participant will be asked to answer the questions.
Description: An online survey will be designed to understand the current clinical conditions and current practice regarding dysphagia management during the pandemic period/normalization period
Measure: Online survey Time: 3 monthsThe aim of this study is to evaluate the efficacy of an optimal-massive intervention (OMI) based on increasing shear viscosity of fluids, nutritional support with oral nutritional supplements (ONS) and triple adaptation of food (rheological and textural, caloric and protein and organoleptic) and oral hygiene improvement on the incidence of respiratory infections in older patients with OD. We have designed a randomized clinical trial, with two parallel arms and 6 months follow-up. The study population will be constituted by older patients of 70 years or more with OD hospitalized at Hospital de Mataró by an acute process that will be identified by using the volume-viscosity swallow clinical test. We will consecutively recruit 500 subjects during admission (Geriatrics, Internal medicine, etc.) at the Hospital de Mataró. Patients included will be randomly assigned to one of both interventional groups: a) study intervention: multifactorial intervention based on fluid viscosity adaptation (with a xanthan gum thickener -> Nutilis Clear®), nutritional support with a triple adaptation of food (texture, caloric and protein content, organoleptic) + pre-thickened ONS and evaluation and treatment of oral hygiene (tooth brushing + antiseptic mouthwashes + professional dental cleaning), or b) control intervention: standard clinical practice (fluid adaptation with Nutilis Powder and simple texture adaptation for solids). Main outcome measures: respiratory infection incidence during the 6-month period follow-up. Secondary outcomes: mortality at 6 months, general hospital readmissions and readmissions due to respiratory infections, nutritional status, hydration status, quality of life, functional status, oral hygiene and dysphagia severity and its relationship with other study variables.
Description: Respiratory infections incidence (includes LRTI, pneumonia and exacerbations of COPD): all new episodes of respiratory infections recorded in the clinical history or in the reports presented by the patient will be recorded. LRTI: presence of at least 2 of the following symptoms without other cause to explain them: fever, cough, purulent expectoration, rhonchi or wheezing. Pneumonia: performing 1 or more radiographic tests with new condensation, fever or leukopenia or leukocytosis and at least: cough, purulent expectoration, dyspnea, tachypnea, suggestive auscultation or worsening of gas exchange. COPD exacerbation: acute exacerbation of COPD is a sudden worsening of COPD symptoms (shortness of breath, quantity and color of phlegm) that typically lasts for several days. It may be triggered by an infection with bacteria or viruses or by environmental pollutants.
Measure: Respiratory infections incidence. Time: From discharge to 6 months follow-upDescription: Mortality: the date and reason for death will be recorded (hospitalization, 1, 3 and 6 months).
Measure: Mortality Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: General readmissions and readmissions for respiratory infections (1, 3 and 6 months): LRTI, pneumonia and exacerbations of COPD: the reason for admission will be that stated in the hospital database (CMBDAH) according to CIM-10. The information source of the readmissions will be the registration of hospital discharges that is integrated into the hospital information system and that includes the CIM-10 codes of the main and secondary diagnoses of the episode that caused the admission, the date of admission and discharge and the days of hospitalization. Readmissions from pneumonia (codes CIM-10): J13, J18.1, J15.1, J14, J15.4, J15.211, J15.5, A48.1, J15.8, J18.0, J18.8, J69.0; readmissions for LRTI (no pneumonic): J20.0 - J20.9, J10.1, J11.1, J41.8, J44.1 and J44.0. Readmissions from exacerbation of COPD: J441.
Measure: General readmissions and readmissions for respiratory infections Time: Through study completion, at 1, 3 and 6 months from disharge.Description: Mini-nutritional assessment form (MNA) (hospitalization, 1, 3 and 6 months).
Measure: Nutritional status (MNA) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Heigh in cm (hospitalization, 1, 3 and 6 months).
Measure: Nutritional status (Anthropometric measures) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Weight in kg (hospitalization, 1, 3 and 6 months).
Measure: Nutritional status (Anthropometric measures2) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Biochemical parameters from blood analysis (hospitalization, 3 and 6 months).
Measure: Nutritional status (Biochemical parameters) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Hydration status: we will register total body water and intracellular water with bioimpedance (hospitalization, 1, 3 and 6 months).
Measure: Hydration status (bioimpedance) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Quality of life: EQ-5D questionnaire will be used (hospitalization, 1, 3 and 6 months).
Measure: Quality of life of patients during the study period Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Functional status: we will use the Barthel Index (hospitalization, 1, 3 and 6 months).
Measure: Functional status Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Oral Hygiene: the OHI-S (simplified oroal hygiene index) will be collected (hospitalization, 1, 3 and 6 months).
Measure: Oral Hygiene Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Severity of dysphagia: according to the different viscosities that patients will be able to swallow and with the Functional Oral Intake Scale (V-VST/FOIS) (hospitalization, 1, 3 and 6 months).
Measure: Dysphagia severity Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Sociodemographic characteristics of the study population.
Measure: Sociodemographics Time: BaselineDescription: Swallowing function (V-VST) (hospitalization, 1, 3 and 6 months).
Measure: Swallowing function (V-VST) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Rate of institutionalization (1, 3 and 6 months).
Measure: Institutionalization Time: Through study completion, at 1, 3 and 6 months from disharge.Description: Drugs taken by the patient.
Measure: Pharmacological treatment Time: BaselineDescription: Geriatric syndromes
Measure: Geriatric syndromes Time: BaselineDescription: Fried criteria (hospitalization, 1, 3 and 6 months).
Measure: Frailty 1 Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Edmonton frail scale (hospitalization, 1, 3 and 6 months).
Measure: Frailty 2 Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Smoking and alcohol consumption
Measure: Toxic habits Time: BaselineDescription: Compliance with the recommendations of the study intervention (adaptations of fluid, prescribed diets and oral hygiene) (hospitalization, 1, 3 and 6 months).
Measure: Compliance Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Palatability of the intervention products will be measured with the 5-point facial hedonic scale (hospitalization, 1, 3 and 6 months).
Measure: Palatability Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Acceptability of the dietes will be measured with the Food Action Rating Scale (hospitalization, 1, 3 and 6 months)
Measure: Acceptability Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.This study examines the presence, severity and natural history of dysphagia and dysphonia in the post-extubation and severely unwell COVID-19 patient.
Description: Based on therapy outcome measures from FEES, VoiS
Measure: Primary endpoint is severity of dysphonia and dysphagia at the time of initial assessment t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation). Time: t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: The severity of dysphonia and/or dysphagia over an initial 12 month period (at t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months) Time: t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: The severity of dysphonia and/or dysphagia at t = day 5, day 10, day 14, day 21 - For in-patients only. Time: t = day 5, day 10, day 14, day 21 - For in-patients only.Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with grade of ARDS Time: t = day 0 and 9 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with length of intubation Time: t = day 0 and 9 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with duration of mechanical ventilation Time: t = day 0 and 9 monthsDescription: Questionnaire assessment: This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28
Measure: Relationship between severity of dysphonia on quality of life using Voice Symptom Scale (VoiSS) questionnaire over time at day 0, 1 month and 9 months. Time: t = day 0, 1 month and 9 months.Description: Questionnaire assessment: This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
Measure: Relationship between severity of dysphagia on quality of life using Dysphagia Handicap Index (DHI) questionnaire over time at day 0, 1 month and 9 months Time: t = day 0, 1 month and 9 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports